IsoTis licenses skin product amid ongoing cutbacks
This article was originally published in Clinica
Executive Summary
IsoTis has announced a licensing deal for its wound management portfolio with Healthpoint. The opportunity to cash in on its development so far without investing any more in bringing the products to market led its share price to rise by 6.15% to SwFr2.76 by the early afternoon on the day of the announcement (August 18).